NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









ETERN Therapeutics

ETERN Therapeutics

Private
ShanghaiHealthcare & Life Scienceshttp://eterntx.com/

Last Round

Series B

Extension

Jun 26, 2026

Total Funding Raised

$13.4M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

ETERN Therapeutics is a biotechnology company that develops novel small molecule drugs targeting undruggable proteins using a proprietary liquid-liquid phase separation (LLPS) technology platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

liquid-liquid phase separationLLPSsmall-molecule drugdrug discovery platformundruggable targetsoncology drug developmentbiotechcomputer-aided drug designCADDSHP2 inhibitorFGFR antagonistprotein dynamic structureAI-augmented drug discoverypharma R&Dprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ETERN Therapeutics Comps

Public and private peers based on sector, stage, and business model.

ETERN Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

ETERN Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionJun 26, 2026
Series B ExtensionApr 1, 2024
Series BSep 1, 2021
Series AApr 9, 2020
AngelDec 31, 2018
Angel
Dec 1, 2018

Key People

Founding team and executive leadership

Jidong Zhu

Co-Founder And CEO

Founding Team

ETERN Therapeutics Investors

Notable investors and investment history

ETERN Therapeutics investors
InvestorRounds
Hillhouse InvestmentSeries B
TF CapitalSeries B, Series A
Morningside VenturesSeries B
Wuxi High-tech Zone Venture Capital Holding GroupSeries B Extension
BOHE Angel FundSeries A
Wuxi Capital Group Co.,LtdSeries B Extension
Apricot CapitalSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 21, 2026

    Monthly visitors increased 59% MoM.

  • Sep 1, 2021

    Led by Hillhouse Investment and Astrazeneca-CICC Healthcare Industrial Fund.

ETERN Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ETERN Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ETERN Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range7
Year Founded2018
Last FundingJun 26, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.